Tirzepatide
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 252
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part A: Bimagrumab Dose 2 + Tirzepatide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 1 + Tirzepatide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Placebo + Tirzepatide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |